



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/72	A1	(11) International Publication Number: WO 93/05792 (43) International Publication Date: 1 April 1993 (01.04.93)
(21) International Application Number: PCT/EP92/02133 (22) International Filing Date: 14 September 1992 (14.09.92) (30) Priority data: PD91A000163 16 September 1991 (16.09.91) IT (71) Applicant: FIDIA S.P.A. [IT/IT]; Via Ponte della Fabbrica, 3/A, I-35031 Abano Terme (IT). (72) Inventors: ROMEO, Aurelio ; Viale Ippocrate, 93, I-00161 Rome (IT). TOFFANO, Gino ; Via de Amicis, 2, I-35036 Montegrotto Terme (IT). CALLEGARO, Lanfranco ; Via Bravi, 35, I-35020 Ponte di Brenta (IT).		(74) Agents: HIRSCH, Marc-Roger et al.; 34, rue de Bassano, F-75008 Paris (FR). (81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report. Before the expiration of the time-limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: NEW USE OF ACIDIC POLYSACCHARIDE ESTERS AS ANTI-ULCER AGENTS (57) Abstract Acidic polysaccharide esters containing carboxylic groups are useful for protecting against and curing ulcers of the gastroenteric system. These esters include choline esters with acidic polysaccharides chosen from the group formed by hyaluronic acid, alginic acid, gellan, oxidized-cellulose, oxidized chitin, carboxy-hydrocarbyl-cellulose, carboxy-hydrocarbyl-starch and carboxy-hydrocarbyl-chitin, wherein hydrocarbyl means the residue of a hydrocarbon chosen from the group formed by alkyl, aralkyl and cycloalkyl.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	ML	Mali	UA	Ukraine
ES	Spain			US	United States of America

NEW USE OF ACIDIC POLYSACCHARIDE ESTERS AS ANTI-ULCER AGENTS

SUMMARY OF THE INVENTION

The present invention is directed to a new use of
5 acidic polysaccharide esters containing carboxylic
groups. More precisely, the invention concerns the use
of choline esters with acidic polysaccharides chosen
from the group formed by hyaluronic acid, alginic
acid, gellan, oxidized cellulose, oxidized chitin,
10 carboxy-hydrocarbyl-cellulose,
carboxy-hydrocarbyl-starch and
carboxy-hydrocarbyl-chitin, wherein hydrocarbyl means
the residue of a hydrocarbon chosen from the group
formed by alkyl, aralkyl and cycloalkyl. It has been
15 found that these esters are remarkably active in
protecting against and curing ulcers of the
gastro-enteric system, and that they can therefore be
used to advantage in the corresponding therapies.

The esters of said acidic polysaccharides with
20 choline are known and are described in European patent
applications Nos. 86305233.8, filed 7 July 1986,
87401464.0, filed 25 June 1987, and 89108628.2, filed
12 May 1989. Their use, as described in these patent
applications, comes within the scope of the
25 applications of the esters in general mentioned
therein. These include use in the pharmaceutical
sector alone, their use in preparations wherein the
pharmacological action of the polysaccharide itself is
to be exploited, such as in the case of hyaluronic
30 acid in therapy for arthropathies or in ophthalmic
surgery, or in preparations in which the esterifying
alcoholic component is a substance with a
pharmacological activity of its own which is to be

SUBSTITUTE SHEET

exploited and in which therefore the polysaccharide component acts essentially as the vehicle alone. The latter use is exemplified in the case again of hyaluronic esters, hyaluronic acid esters with
5 steroidal alcohols and with alcohols having an antibacterial action. This is also true of the esters of the other acidic polysaccharides mentioned above.

The anti-ulcer properties of the choline esters of said acidic polysaccharides are derived from the
10 polysaccharide component, as the gelling and protective effect of some of said polysaccharides on the mucosa is well known. Such qualities have been described especially for alginic acid and its application is envisaged as a curative agent in
15 gastric inflammation processes.

As another example in the prior art, the sodium salt of an alginic acid derivative comprising a carboxymethyl ether of one of its hydroxy groups, described in US patent No. 2,902,479, can be used as
20 an anti-acid agent for the cure of gastric disorders.

It has now been discovered, according to the present invention, that the choline esters with the acidic polysaccharides listed above possess a protective anti-ulcer effect on the gastric mucosa
25 which is very pronounced and greater than that of the known products based on acidic polysaccharides. In the pharmacological experiments reported hereafter, some of the best known protective agents for the gastric mucosa found on the market are also compared
30 to some products of the present invention.

The object of the present invention is therefore the use of a choline ester with a carboxylic acidic polysaccharide or one of its molecular fractions chosen from the group formed by hyaluronic acid,
35 alginic acid, gellan, oxidized cellulose, oxidized chitin, carboxy-hydrocarbyl-cellulose, carboxy-hydrocarbyl-starch and

carboxy-hydrocarbyl-chitin, wherein the named hydrocarbyl residue is selected from the group consisting of alkyl, aralkyl and cycloalkyl, as an anti-ulcer and gastroprotective agent.

5 The esters to be used according to the invention may be total or partial esters, that is, esters wherein all of the carboxy groups are esterified with choline, or respectively, wherein only part of the carboxyls are thus esterified. As a rule, the
10 quaternary ammonium groups in the partial esters are salified with carboxyls which have remained free. Should 50% or less of the carboxy groups of the polysaccharide be esterified, the carboxy groups which are not thus internally salified and which are still
15 free, can be salified in their turn with metals or organic bases, as described hereafter.

 The basic polysaccharides mentioned above can have molecular weights varying within suitable limits, like those of the natural materials extracted from
20 plants and animals which contain them, or those which have been chemically or physically modified. Thus, one may use either whole polysaccharides or their molecular fractions. In the present description, the term "acidic polysaccharides" can be taken to mean
25 either the whole acids or their molecular fractions. When choline esters are used with a hyaluronic acid, it is possible to use basic hyaluronic acids extracted from cockscombs and purified according to the methods described in the literature.

30 Particularly suitable for this use are molecular fractions of hyaluronic acid purified with molecular weights which can vary within wide limits, for example, from about 90-80% to 0.2% of the molecular weight of the whole acid, preferably between 5% and
35 0.2% by weight. Such fractions can be obtained by various procedures described in the literature, that is, by means of hydrolysis, oxidation or enzymatic

procedures or physical procedures, for example, mechanical procedures or by radiation. Accordingly, primordial extracts of the purification process are often formed.

5 The molecular fractions obtained are separated and purified by known techniques, such as, by molecular filtration. One purified fraction of hyaluronic acid, suitable for use according to the invention, is for example that known as

10 "noninflammatory-NIF-NaHA sodium hyaluronate", described by Balazs in the brochure entitled "Healon - A guide to its use in ophthalmic surgery", D. Miller & Stegmann, eds., John Wiley & Sons, N.Y. 81983, p. 5. Of particular importance as starting materials for the

15 esters of the present invention are two purified fractions obtainable from hyaluronic acid, for example, those extracted from hens' crests, known as "Hyalastine" and "Hyalectin" described in the literature, for example, in EP patent No. 0138572.

20 The fraction "Hyalastine" has a mean molecular weight of about 50,000 to 100,000, while the fraction "Hyalectin" has a mean molecular weight of about 500,000 to 730,000. Another fraction has been isolated which is a combination of these two, and it has been

25 characterized as having a mean molecular weight of about 250,000 to 350,000. This combined fraction can be obtained with a yield of 80% of the total hyaluronic acid available from the particular starting material, while the fraction "Hyalectin" can be

30 obtained with a yield of 30% and the fraction "Hyalastine" with a yield of 50% of the starting hyaluronic acid.

 The alginic acid used in the preparation of choline esters can be of various origins and can have

35 a variety of molecular weights. The degree of polymerization of this polysaccharide, formed from D-mannuronic and L-glucuronic acid, varies according

to the kind of algae used for its extraction (for example *Phaeophyceae*), the time of year and the place where it was gathered and the age of the plant.

Alginic acid can also be obtained by microbiological means, for example, by fermentation with *Pseudomonas aeruginosa* or mutants of *Pseudomonas putida*, *Pseudomonas fluorescens* and *Pseudomonas mendocina*. For the preparation of choline esters according to the present invention, alginic acids of either low molecular weight of about 20,000, or high molecular weight of about 400,000 are preferred.

The non-acidic, basic polysaccharides used for the preparation of said acidic polysaccharides containing the carboxy group (cellulose or chitin oxidate) or the hydrocarbyl carboxy group can also have molecular weights which vary within wide limits, such as especially native materials extracted from plants and animals, or those modified by chemical-physical action. Cellulose, for example, can be native cellulose from cotton with about 3,000 units of D-glucose, or regenerated, for example mercerized cellulose, or cellulose degraded for example by the action of mineral acids or enzymes. The starch can come from any type of plant, for example potatoes or cereals, and therefore may contain variable quantities of the two ordinary starch components, amylose and amylopectin. It is also possible to use starches mainly containing for example amylopectin, such as those derived from certain types of wheat, sorghum, oats or rice, and it is possible to use also the 2-amylose and amylopectin fractions obtained by separation according to known methods. Finally, it is also possible to use partially hydrolyzed starches as a starting material.

The chitin used in the preparation of oxidized chitin or carboxy-hydrocarbyl-chitin, to be used in turn in the preparation of choline esters according to

the invention, is for example that extracted from fungi or algae. Derivatives thereof obtained by partial hydrolysis can also be used.

Among all of these polysaccharides, it is
5 preferable to use the commercially available products.

In the aforesaid carboxy-hydrocarbyl-derivatives of cellulose, starch and chitin, the hydrocarbyl group is chosen from alkyl, aralkyl and cycloalkyl. Alkyl is above all a lower alkyl,
10 especially a straight-chained alkyl, with a maximum of 6 carbon atoms. Alkyl is preferably the methyl group. Aralkyl is preferably a group derived from a pure alkyl having a maximum of 6 carbon atoms, especially methyl, and in which the aryl group is a benzene
15 residue, unsubstituted or substituted by 1-3 lower alkyl groups having a maximum of 4 carbon atoms, especially methyl or hydroxy or alkoxy groups having a maximum of 4 carbon atoms. A cycloalkyl group is preferably a group with a maximum of 6 carbon atoms in
20 the ring, especially between 3 and 6 atoms, which can be substituted by 1 to 3 lower alkyl groups, especially methyl groups.

The partial esters of choline with the aforesaid acidic polysaccharides can also be used as inner salts
25 obtained directly by esterification or in the form of their metal salts or therapeutically acceptable organic bases. This use constitutes a preferential object of the present invention. Of particular importance are the salts of alkali or alkaline earth
30 metals, such as in particular sodium, potassium, ammonium, calcium or magnesium salts.

The therapeutically acceptable organic bases for the preparation of salts to be used according to the invention should preferably be free from
35 pharmacological activity of their own, while not excluding pharmacologically active bases with an action which is compatible with the intended antiulcer

and gastroprotective use. Such bases include bases having a spasmolytic action or antagonists of histamine H_2 -receptors such as cimetidine, ranitidine or ticlopidine. Examples of pharmacologically inert bases are aliphatic amines, for example mono-, di-, and trialkylamines with alkyl groups having a maximum of 6 carbon atoms, or arylalkylamines with the same number of carbon atoms in the aliphatic part or where aryl means a benzene group, optionally substituted by 1 to 3 methyl groups, halogen atoms, hydroxy groups or alkoxy groups such as methoxy groups. The bases can be cyclic, such as monocyclic alkylene amines with rings of 4 to 6 carbon atoms, optionally interrupted in the carbon atom chain by heteroatoms chosen from the group formed by oxygen, nitrogen and sulfur, such as piperidine or morpholine. The bases can also be substituted by amino or hydroxy functions, such as aminoethanol or choline itself. Quaternary ammonium salts of these basic groups can also be formed, such as tetraalkylammonium salts, for example, tetramethylammonium or higher homologues, such as those having a maximum of 4 carbon atoms in the alkyl groups.

The superior gastroprotective activity of the choline esters with the aforesaid acidic polysaccharides according to the present invention has been demonstrated by pharmacological experiments performed on two esters of an alginic acid with choline, being thus identified:

Alau 0101 - p.40 = alginic acid ester with a molecular weight of 200,000 with choline as described in Example 5

Alau 0801 - p.40 = alginic acid ester with a molecular weight of 70,000 with choline as described in Example 6

and on commercially available gastroprotective products, and more exactly with:

sucralfate = octasulfonic saccharose ester aluminum salt

- 5 Maalox TC = aluminum and magnesium hydroxides
Gaviscon = sodium alginate, sodium bicarbonate
and on alginic acid itself.

1. Gastric lesions induced by reserpine

Description of the model

- 10 The study was performed on male Sprague-Dawley rats (170-190 g) housed in metabolic cages and denied food for 48 hours before the tests (but with free access to water).

- 15 The test products were administered orally (gastric tube) twice, immediately before reserpine injection and two hours later, at doses of 200-400 mg/kg in 15 ml/kg of distilled water.

The following products were tested:

- 20 - Alau 0101
- Alau 0801
- sucralfate
- alginic acid

- 25 The controls were kept under the same experimental conditions and received 15 ml/kg of physiological saline solution.

- 30 Reserpine was injected i.p. at a dose of 20 mg/kg (in 10 ml/kg of a 0.5% solution of acetic acid). The animals were sacrificed 4 hours later and their stomachs removed and opened along the greater curvature, washed with saline solution, fixed into position and observed under a magnifying glass.

Parameters

The gastric lesions were assessed in two ways:

- a) on the basis of the number of ulcers present in the mucosa (regardless of their dimensions).
- 5 b) on the basis of a score of gastrolesions according to the following scale:
- | | | | |
|----|-----|---|---|
| | 0 | = | no lesions |
| | 0.5 | = | widespread hyperemia |
| | 1 | = | 1-2 punctate ulcers |
| 10 | 2 | = | 3-10 punctate ulcers |
| | 3 | = | >10 punctate ulcers and/or 1 large ulcer |
| | 4 | = | 2 or more large ulcers, or 1 or more perforating ulcers |

15 Results

The results obtained (Table 1) indicate that:

- Alau 0101 and Alau 0801 have a marked gastroprotective activity. The effect is dose-dependent and evident at as low a dose as 200 mg/kg os (the percentage of protection with regard to the number of ulcers present in the mucosa of controls treated with saline was 54% and 51% respectively), reaching maximum activity at a dose of 400 mg/kg os (percentage of protection was 94% and 90% respectively);
- the efficacy of Alau 0101 and Alau 0801 is greater than that of sucralfate (26% of protection at 400 mg/kg), while alginic acid alone is ineffective.

SUBSTITUTE SHEET

It can therefore be concluded that both Alau derivatives have a marked protective activity in a model in which the ulcerogenic effect of reserpine is essentially correlated with the release of serotonin from the mast cells.

TABLE 1:

Effect of Alau 0101 and Alau 0801 (vs sucralfate and alginic acid) on gastric lesions induced by reserpine

Group (No)	Treatment os	dose mg/kg x 2	mean No. ulcers per rat \pm S.E.	mean gastric lesions \pm S.E.
I (30)	Saline	15 ml/kg	12.60 \pm 0.89 (--)	4.00 \pm 0.00 (--)
II (10)	ALAU 0101	200	5.80 \pm 0.55 (54%)	2.80 \pm 0.13 (30%)
III (10)	ALAU 0101	400	0.80 \pm 0.20 (94%)	0.70 \pm 0.18 (82%)
IV (10)	ALAU 0801	200	6.20 \pm 0.61 (51%)	3.00 \pm 0.15 (25%)
V (10)	ALAU 0801	400	1.20 \pm 0.33 (90%)	0.80 \pm 0.15 (80%)
VI (10)	sucralfate	400	9.30 \pm 1.12 (26%)	2.80 \pm 0.29 (30%)
VII (10)	alginic acid	400	12.30 \pm 1.71 (2%)	4.00 \pm 0.00 (--)

No. corresponds to the number of animals per group

In parentheses the percentage of protection compared to controls treated with saline

2. Gastric lesions induced by serotonin

Description of the model

The study was performed on male Sprague-Dawley rats (150-160 g) housed in metabolic cages and denied

SUBSTITUTE SHEET

food for 48 hrs before the tests (but with free access to water).

The test products (Alau 0101 - sucralfate - Maalox) were tested orally (gastric tube) under three
5 different sets of experimental conditions:

- 1) twofold oral administration (400 mg/kg)
immediately before serotonin injection and 2 hrs
later.
- 10 2) single oral administration (400 mg/kg)
immediately before serotonin injection.
- 3) single oral administration (400 mg/kg) 2 hrs
after serotonin administration.

Under the same experimental conditions, the
controls received 15 ml/kg of physiological saline
15 solution. The serotonin creatine sulfate was injected
s.c. at a dose of 35 mg/kg. The animals were
sacrificed 4 hrs later and their stomachs removed and
opened along the greater curvature, washed with saline
fixed into position and observed under a magnifying
20 glass.

Parameters

The gastric lesions were assessed in 2 different ways:

- a) on the basis of the number of ulcers present in
the mucosa (regardless of their dimensions).
- 25 b) on the basis of a score according to the
following scale:

0 = no lesions

SUBSTITUTE SHEET

	0.5	=	widespread hyperemia
	1	=	1-2 punctate ulcers
	2	=	3-10 punctate ulcers
	3	=	punctate necrosis and/or 1 large ulcer
5	4	=	2 or more large ulcers, or 1 or more perforating ulcers

Results

The results obtained (Table 2) indicate that:

- 10 - Alau 0101 has a gastroprotective activity (91% of protection, after two administrations of 400 mg/kg os, with regard to the number of ulcers present in the mucosa of the saline-treated controls)
- 15 - the effect of Alau is evident even after 1 single administration before ("preventive effect") inducement of the gastric lesion (about 69% protection), while it is less marked (45% protection) when not administered until after the lesion ("curative effect")
- 20 - the efficacy of Alau is greater than that of sucralfate (43% protection at two doses of 400 mg/kg each), and equal to that of Maalox.

25 It can therefore be concluded that Alau 0101 has a valid gastroprotective activity in experimental conditions of gastric lesions induced by serotonin. The data also weigh in favor of an essentially preventive and only partially curative effect.

TABLE 2:

Effect of Alau 0101 (vs sucralfate and Maalox) on gastric lesions induced by serotonin

Group (No.)	Treatment	Dose	Equiv. STD *	Mean No. ulcers per rat \pm S.E.	Mean gastric lesions \pm S.E.
I (30)	Saline	15 ml/kg		15.00 \pm 1.23 (--)	3.90 \pm 0.06 (--)
II (10)	ALAU 0101	400 (mg/kg) x 2	24	1.30 \pm 0.37 (91%)	0.75 \pm 0.17 (81%)
III (10)	Sucralfate	400 (mg/kg) x 2	24	8.50 \pm 0.98 (43%)	2.40 \pm 0.27 (39%)
IV (10)	Maalox TC	6.0 (ml/kg) x 2	24	1.20 \pm 0.36 (92%)	0.70 \pm 0.18 (82%)
V (10)	ALAU 0101	400 mg/kg**		4.60 \pm 0.72 (69%)	1.55 \pm 0.24 (60%)
VI (10)	ALAU 0101	400 mg/kg***		8.20 \pm 1.10 (45%)	2.40 \pm 0.22 (39%)

No. corresponds to the number of animals per group

In parentheses the percentage of protection compared to saline-treated controls

- * Dose expressed in equivalent STD, corresponding to the single dose indicated in therapy
 ** Alau in a single dose before lesion
 *** Alau in a single dose 2 hrs after lesion

3. Gastric lesions induced by ethyl alcohol

Description of the model

The study was performed on male Sprague-Dawley rats (180-200 g) housed in metabolic cages and fed with a 5% glucose solution alone + 0.4% NaCl, but denied all other food for 48 hrs before the tests. The test products (Alau 0101 - sucralfate - Maalox - Gaviscon) were administered orally (at doses of between 200-400 mg/kg) by means of a gastric tube, in 15 ml/kg of saline solution.

Ten minutes after treatment, 1.5 ml/rat of absolute ethyl alcohol were administered. The animals

were sacrificed 1 hr later. Their stomachs were removed, opened along the greater curvature, washed with saline solution, fixed in position and observed under a magnifying glass.

5 Parameters

The gastric lesions were assessed according to the following scale (from 0 to 5):

	0	=	no lesions
	1	=	widespread hyperemia
10	1.5	=	1 hemorrhagic zone
	2	=	2 hemorrhagic zones
	2.5	=	1-2 hemorrhagic zones + punctate lesions
	3	=	3-4 hemorrhagic zones
	4	=	5 hemorrhagic zones (or 3 hemorrhagic zones
15			punctate lesions
	4.5	=	4-5 hemorrhagic zones + punctate lesions
	5	=	6 or more hemorrhagic zones (or 5
			hemorrhagic zones + punctate lesions)

20 The mean gastric lesion rating was therefore indicated on the basis of said scale.

Results

The results obtained (Table 3) indicate that:

- 25 - Alau 0101 has an appreciable gastroprotective activity at a dose of 400 mg/kg (50% of protection compared to saline-treated controls)
- the gastroprotective efficacy of Alau 0101 is greater than that of Gaviscon and sucralfate, while it is comparable to that of Maalox.

TABLE 3:

Effect of Alau 010 (vs sucralfate and Maalox) on gastric lesions induced by ethyl alcohol

Group (No.)	Treatment os	Dose	Equivalent STD *	Mean gastric lesions \pm S.E.
I (20)	Saline	--	--	4.85 \pm 0.08 (--)
II (10)	Alau 0101	200 mg/kg	12	3.60 \pm 0.22 (26%)
III (10)	Alau 0101	400 mg/kg	24	2.45 \pm 0.17 (50%)
IV (10)	Sucralfate	200 mg/kg	12	4.30 \pm 0.11 (11%)
V (10)	Sucralfate	400 mg/kg	24	2.95 \pm 0.14 (39%)
VI (10)	Maalox TC	5 ml/kg	20	2.85 \pm 0.15 (41%)
VII (10)	Gaviscon	2.0 ml/kg	10	4.35 \pm 0.18 (10%)
VIII (10)	Gaviscon	4.0 ml/kg	20	3.25 \pm 0.21 (33%)

- * Dose expressed as STD equivalent corresponding to the single dose indicated in therapy
- No. corresponds to the number of animals per group
- In parentheses the percentage of protection compared to saline-treated controls

The aforesaid results show that the alginic esters of choline have a valuable gastroprotective activity. In particular, it is interesting to emphasize that:

- Alau 0101 and Alau 0801 have a marked gastroprotective activity, especially on gastric lesions induced by reserpine and serotonin:
- The effect is dose-dependent with maximum efficacy after two administrations of 400 mg/kg/os (maximum protection value of 94%)

- 5 - The effect is mainly preventive and only partly curative. Indeed, a notable gastroprotective activity was observed (69%) even after 1 single administration, before inducement of the gastric lesion.
- 10 - The gastroprotective efficacy of Alau 0101 and Alau 0801 is greater than that of sucralfate and Gaviscon (as shown particularly in the aforecited models of gastric lesions and in gastric lesions induced by ethanol) and comparable to that of Maalox (as shown in lesions induced by ethanol and reserpine, respectively). Alginic acid alone is not effective.

15 It is also interesting to observe that the notable gastroprotective activity of the choline esters is fundamentally evident in two models, in which serotonin is directly or indirectly involved. Serotonin has a strong action on the gastric secretion of acids, through its effect on histamine.

20 The present invention also includes pharmaceutical preparations for oral administration, containing a choline ester with said acidic polysaccharides or one of the aforesaid salts of partial esters, in particular those especially

25 mentioned, optionally together with excipients suitable for this form of administration, such as pills, tablets, gelatin capsules, capsules, or as solutions or freeze-dried powders or granules. They contain preferably between 10% and 100% by weight of

30 active compound. Preferred examples of such excipients are in particular anti-acid substances of a basic nature, such as basic magnesium or calcium salts. The excipients can themselves constitute a layer of the tablets or other forms of pharmaceutical

preparations to be used according to the invention. The esters to be used according to the present invention can be prepared according to known procedures, for example, those described in one of the
5 cited European patents for the preparation of esters in general and their salts.

The invention is illustrated by the following Examples:

Example 1:

10 PREPARATION OF THE PARTIAL ESTER OF ALGINIC ACID WITH CHOLINE (5% of the carboxyls esterified)

4.17 g (10 mEq) of the tetrabutylammonium salt of alginic acid, with a molecular weight of 200,000 are solubilized in 160 ml of a mixture of NMP/H₂O 95:5.
15 The solution is cooled to 0°C and to it is added 0.124 g (0.5 mEq) of (2-bromoethyl)trimethylammonium bromide, finely ground and suspended in 10 ml of pure NMP. The suspension is added slowly over 30 minutes, while being constantly stirred. After 2 hours the
20 resulting mixture is heated to 30°C and stirred for 14 hours. To the reaction mixture are added 320 ml of ethyl acetate. The precipitate thus formed is separated by filtration, washed twice with 50 ml of ethyl acetate and then vacuum-dried. The solid matter
25 is solubilized in 150 ml of H₂O containing 1.5 g of NaCl at 4°C. The solution is filtered and precipitated by slowly adding 450 ml of 95% ethanol while stirring. The precipitate, which constitutes the ester named in the heading, is separated by filtration, washed twice
30 with 50 ml of 95% ethanol and once with 50 ml of acetone and lastly vacuum-dried.

Yield = 1.9 g.

Quantitative determination of the choline, performed according to the method of Kannosuke

Fujimori et al. (J. Chromatography 414, 167 [1987]) after alkaline hydrolysis of the product in 0.1N NaOH at 45°C for 30 minutes, shows a choline content of 0.24 mEq/g.

5 Example 2:

PREPARATION OF THE PARTIAL ESTER OF ALGINIC ACID WITH CHOLINE (10% of the carboxyls esterified)

4.17 g (10 mEq) of the tetrabutylammonium salt of alginic acid, with a molecular weight of 200,000, are
10 solubilized in 160 ml of a mixture of NMP/H₂O 95:5. The solution is cooled to 0°C and to it are added 0.247 g (1.0 mEq) of (2-bromoethyl)trimethylammonium bromide finely ground and suspended in 10 ml of pure NMP. The suspension is slowly added over 30 minutes
15 while being constantly stirred. 2 hours later the resulting mixture is heated to 30°C and stirred for 14 hours. To the reaction mixture are added 320 ml of ethyl acetate. The precipitate thus formed is separated by filtration, washed twice with 50 ml of
20 ethyl acetate and finally vacuum-dried. The solid matter is solubilized in 150 ml of H₂O containing 1.5 g of NaCl at 4°C. The solution is filtered and precipitated by slowly adding 450 ml of 95% ethanol while stirring. The precipitate, which constitutes the
25 ester defined in the heading, is separated by filtration, washed twice with 50 ml of 95% ethanol and once with 50 ml of acetone and finally vacuum-dried. Yield = 1.95 g.

Quantitative determination of the choline,
30 performed according to the method of Kannosuke Fujimori et al. (J. Chromatography 414, 167 [1987]) after the product has undergone alkaline hydrolysis in 0.1N NaOH at 45°C for 30 minutes, shows a choline content of 0.48 mEq/g.

Example 3:

PREPARATION OF THE PARTIAL ESTER OF ALGINIC ACID WITH CHOLINE (20% of the carboxyls esterified)

- 4.17 g (10 mEq) of the tetrabutylammonium salt of
5 alginic acid, with a molecular weight of 200,000, are
solubilized in 160 ml of a mixture of NMP/H₂O 95:5.
The solution is cooled to 0°C and to it is added 0.494
g (2.0 mEq) of (2-bromoethyl)trimethylammonium bromide
finely ground and suspended in 10 ml of pure NMP. The
10 suspension is slowly added over 30 minutes while being
constantly stirred. 2 hours later the resulting
mixture is heated to 30°C and stirred for 14 hours.
To the reaction mixture are added 320 ml of ethyl
acetate. The precipitate thus formed is separated by
15 filtration, washed twice with 50 ml of ethyl acetate
and finally vacuum-dried. The solid matter is
solubilized in 150 ml of H₂O containing 1.5 g of NaCl
at 4°C. The solution is filtered and precipitated by
slowly adding 450 ml of 95% ethanol while stirring.
20 The precipitate, which constitutes the ester defined
in the heading, is separated by filtration, washed
twice with 50 ml of 95% ethanol and once with 50 ml of
acetone and finally vacuum-dried.
Yield = 2.01 g.
25 Quantitative determination of the choline,
performed according to the method of Kannosuke
Fujimori et al. (J. Chromatography 414, 167 [1987])
after the product has undergone alkaline hydrolysis in
NaOH 0.1N at 45°C per 30 minutes, shows a choline
30 content of 0.95 mEq/g.

Example 4:

PREPARATION OF THE PARTIAL ESTER OF ALGINIC ACID WITH CHOLINE (30% of the carboxyls esterified)

4.17 g (10 mEq) of the tetrabutylammonium salt of

alginic acid, with a molecular weight of 200,000, are solubilized in 160 ml of a mixture of NMP/H₂O 95:5. The solution is cooled to 0°C and to it is added 0.741 g (3.0 mEq) of (2-bromoethyl)trimethylammonium bromide
5 finely ground and suspended in 10 ml of pure NMP. The suspension is slowly added over 30 minutes while being constantly stirred. 2 hours later the resulting mixture is cooled to 30°C and stirred for 14 hours. To the reaction mixture are added 320 ml of ethyl
10 acetate. The precipitate thus formed is separated by filtration, washed twice with 50 ml of ethyl acetate and finally vacuum-dried. The solid matter is solubilized in 150 ml of H₂O containing 1.5 g of NaCl at 4°C. The solution is filtered and precipitated by
15 slowly adding 450 ml of 95% ethanol while stirring. The precipitate, which constitutes the ester defined in the heading, is separated by filtration, washed twice with 50 ml of 95% ethanol and once with 50 ml of acetone and finally vacuum-dried.
20 Yield = 2.05 g.

Quantitative determination of the choline, performed according to the procedure Kannosuke Fujimori et al. (J. Chromatography 414, 167 [1987]) after the product has undergone alkaline hydrolysis in
25 NaOH 0.1N at 45°C for 30 minutes, shows a choline content of 1.40 mEq/g.

Example 5:

PREPARATION OF THE PARTIAL ESTER OF ALGINIC ACID WITH CHOLINE (40% of the carboxyls esterified)

30 4.17 g (10 mEq) of the tetrabutylammonium salt of alginic acid, with a molecular weight of 200,000, are solubilized in 160 ml of a mixture of NMP/H₂O 95:5. The solution is cooled to 0°C and to it is added 1.087 g (4.4 mEq) of (2-bromoethyl)trimethylammonium bromide
35 finely ground and suspended in 10 ml of pure NMP. The

suspension is slowly added over 30 minutes while being stirred. After 2 hours the resulting mixture is heated to 30°C and stirred for 14 hours.

To the reaction mixture are added 320 ml of ethyl acetate. The precipitate thus formed is separated by filtration, washed twice with 50 ml of ethyl acetate and finally vacuum-dried. The solid matter is solubilized in 150 ml of H₂O containing 1.5 g of NaCl at 4°C. The solution is filtered and precipitated by slowly adding 450 ml of 95% ethanol while stirring. The precipitate, which constitutes the ester defined in the heading, is separated by filtration, washed twice with 50 ml of 95% ethanol and once with 50 ml of acetone and finally vacuum-dried.

Yield = 2.03 g.

Quantitative determination of the choline, performed according to the procedure of Kannosuke Fujimori et al. (J. Chromatography 414, 167 [1987]) after the product has undergone alkaline hydrolysis in NaOH 0.1N at 45°C for 30 minutes, shows a choline content of 1.85 mEq/g.

Example 6:

PREPARATION OF THE PARTIAL ESTER OF ALGINIC ACID WITH CHOLINE (40% of the carboxyls esterified)

4.17 g (10 mEq) of the tetrabutylammonium salt of alginic acid, with a molecular weight of 200,000 and having a high mannuronic content, are solubilized in 160 ml of a mixture of NMP/H₂O 95:5. The solution is cooled to 0°C and to it are added 1.087 g (4.4 mEq) of (2-bromoethyl)trimethylammonium bromide finely ground and suspended in 10 ml of pure NMP. The suspension is slowly added over 30 minutes while being constantly stirred. After 2 hours the resulting mixture is heated to 30°C and stirred for 14 hours. To the reaction mixture are added 320 ml of

ethyl acetate. The precipitate thus formed is separated by filtration, washed twice with 50 ml of ethyl acetate and finally vacuum-dried. The solid matter is solubilized in 150 ml of H₂O containing 1.5 g of NaCl at 4°C. The solution is filtered and precipitated by slowly adding 450 ml of 95% ethanol while stirring. The precipitate, which constitutes the ester defined in the heading, is separated by filtration, washed twice with 50 ml of 95% ethanol and once with 50 ml of acetone and finally vacuum-dried. Yield = 2.03 g.

Quantitative determination of the choline performed according to the procedure of Kannosuke Fujimori et al. (J. Chromatography 414, 167 [1987]) after the product has undergone alkaline hydrolysis in NaOH 0.1N at 45°C for 30 minutes, shows a choline content of 1.85 mEq/g.

Example 7:

PREPARATION OF THE PARTIAL ESTER OF ALGINIC ACID WITH CHOLINE (40% of the carboxyls esterified)

4.17 g (10 mEq) of the tetrabutylammonium salt of alginic acid, with a molecular weight of 70,000, are solubilized in 160 ml of a mixture of NMP/H₂O 95:5. The solution is cooled to 0°C and to it are added 1.087 g (4.4 mEq) of (2-bromoethyl)trimethylammonium bromide finely ground and suspended in 10 ml of pure NMP. The suspension is slowly added over 30 minutes while being constantly stirred. After 2 hours the resulting mixture is heated to 30°C and stirred for 14 hours. To the reaction mixture are added 320 ml of ethyl acetate. The precipitate thus formed is separated by filtration, washed twice with 50 ml of ethyl acetate and finally vacuum-dried. The solid matter is solubilized in 150 ml of H₂O containing 1.5 g of NaCl at 4°C. The solution is filtered and then

precipitated by adding 450 ml of 95% ethanol while stirring. The precipitate, which constitutes the ester defined in the heading, is separated by filtration, washed twice with 50 ml of 95% ethanol and once with 50 ml of acetone and finally vacuum-dried. Yield = 2.03 g.

Quantitative determination of the choline, performed according to the procedure of Kannosuke Fujimori et al. (J. Chromatography 414, 167 [1987]) after the product has undergone alkaline hydrolysis in NaOH 0.1N at 45°C for 30 minutes, shows a choline content of 1.85 mEq/g.

Example 8:

PREPARATION OF THE PARTIAL ESTER OF A
15 CARBOXYMETHYLCELLULOSE WITH CHOLINE (30% of the carboxyls esterified)

4.62 g (10 mEq) of the tetrabutylammonium salt of a carboxymethylcellulose with a degree of substitution = 1.0, are solubilized in 160 ml of a mixture of
20 NMP/H₂O 95:5.

The solution is cooled to 0°C and to it are added 0.71 g (3.0 mEq) of (2-bromoethyl)trimethylammonium bromide finely ground and suspended in 10 ml of pure NMP. The suspension is slowly added over 30 minutes while
25 stirring. After 2 hours the resulting mixture is heated to 30°C and stirred for 14 hours.

To the reaction mixture are added 320 ml of ethyl acetate. The precipitate thus formed is separated by filtration, washed twice with 50 ml of ethyl acetate
30 and finally vacuum-dried. The solid matter is solubilized in 150 ml of H₂O containing 1.5 g of NaCl at 4°C. The solution is filtered and precipitated by slowly adding 450 ml of 95% ethanol while stirring. The precipitate, which constitutes the ester defined
35 in the heading, is separated by filtration, washed

twice with 50 ml of 95% ethanol and once with 50 ml of acetone and finally vacuum-dried.

Yield = 2.50 g.

- Quantitative determination of the choline, performed according to the procedure of Kannosuke Fujimori et al. (J. Chromatography 414, 167 [1987]) after the product has undergone alkaline hydrolysis in NaOH 0.1N at 45°C for 30 minutes, shows a choline content of 1.16 mEq/g.

10 Example 9:

PREPARATION OF THE PARTIAL ESTER OF A CARBOXYMETHYLCELLULOSE WITH CHOLINE (40% of the carboxyls esterified)

- 4.62 g (10 mEq) of the tetrabutylammonium salt of a carboxymethylcellulose having a degree of substitution = 1.0, are solubilized in 160 ml of a mixture of NMP/H₂O 95:5.

- The solution is cooled to 0°C and to it are added 1.09 g (4.4 mEq) of (2-bromoethyl)trimethylammonium bromide finely ground and suspended in 10 ml of pure NMP. The suspension is slowly added over 30 minutes while being constantly stirred. 2 hours later the resulting mixture is heated to 30°C and stirred for 14 hours.

- To the reaction mixture are added 320 ml of ethyl acetate. The precipitate thus formed is separated by filtration, washed twice with 50 ml of ethyl acetate and finally vacuum-dried. The solid matter is solubilized in 150 ml of H₂O containing 1.5 g of NaCl at 4°C. The solution is filtered and precipitated by slowly adding 450 ml of 95% ethanol while stirring. The precipitate, which constitutes the ester defined in the heading, is separated by filtration, washed twice with 50 ml of 95% ethanol and once with 50 ml of acetone and finally vacuum-dried.

- 35 Yield = 2.80 g.

Quantitative determination of the choline, performed according to the procedure Kannosuke Fujimori et al. (J. Chromatography 414, 167 [1987]) after the product has undergone alkaline hydrolysis in NaOH 0.1N at 45°C for 30 minutes, shows a choline content of 1.38 mEq/g.

Example 10:

PREPARATION OF A PARTIAL ESTER OF A CARBOXYMETHYLCELLULOSE WITH CHOLINE (30% of the carboxyls esterified)

5.16 g (10 mEq) of the tetrabutylammonium salt of a carboxymethylcellulose having a degree of substitution = 0.75, are solubilized in 160 ml of a mixture of NMP/H₂O 95:5.

The solution is cooled to 0°C and to it is added 0.71 g (3.0 mEq) of (2-bromoethyl)trimethylammonium bromide finely ground and suspended in 10 ml of pure NMP. The suspension is slowly added over 30 minutes while being constantly stirred. 2 hours later the resulting mixture is heated to 30°C and stirred for 14 hours. To the reaction mixture are added 320 ml of ethyl acetate. The precipitate thus formed is separated by filtration, washed twice with 50 ml of ethyl acetate and finally vacuum-dried. The solid matter is solubilized in 150 ml of H₂O containing 1.5 g of NaCl at 4°C. The solution is filtered and precipitated by slowly adding 450 ml of 95% ethanol while stirring. The precipitate, which constitutes the ester defined in the heading, is separated by filtration, washed twice with 50 ml of 95% ethanol and once with 50 ml of acetone and finally vacuum-dried.

Yield = 3.02 g.

Quantitative determination of the choline, performed according to the procedure of Kannosuke Fujimori et al. (J. Chromatography 414, 167 [1987])

after the product has undergone alkaline hydrolysis in NaOH 0.1N at 45°C for 30 minutes, shows a choline content of 0.96 mEq/g.

Example 11:

5 PREPARATION OF A PARTIAL ESTER OF A
CARBOXYMETHYLCELLULOSE WITH CHOLINE (40% of the
carboxyls esterified)

5.16 g (10 mEq) of the tetrabutylammonium salt of
a carboxymethylcellulose with a degree of substitution
10 = 0.75, are solubilized in 160 ml of a mixture of
NMP/H₂O 95:5.

The solution is cooled to 0°C and to it are added
1.087 g (4.4 mEq) of (2-bromoethyl)trimethylammonium
bromide finely ground and suspended in 10 ml of pure
15 NMP. The suspension is slowly added over 30 minutes
while being constantly stirred. 2 hours later the
resulting mixture is heated to 30°C and stirred for 14
hours. To the reaction mixture are added 320 ml of
ethyl acetate. The precipitate thus formed is
20 separated by filtration, washed twice with 50 ml of
ethyl acetate and finally vacuum-dried. The solid
matter is solubilized in 150 ml of H₂O containing 1.5 g
of NaCl at 4°C. The solution is filtered and
precipitated by slowly adding 450 ml of 95% ethanol
25 while stirring. The precipitate, which constitutes the
ester defined in the heading, is separated by
filtration, washed twice with 50 ml of 95% ethanol and
once with 50 ml of acetone and finally vacuum-dried.
Yield = 3.06 g.

30 Quantitative determination of the choline,
performed according to the procedure of Kannosuke
Fujimori et al. (J. Chromatography 414, 167 [1987])
after the product has undergone alkaline hydrolysis in
NaOH 0.1N at 45°C for 30 minutes, shows a choline
35 content of 1.25 mEq/g.

Example 12:PREPARATION OF THE PARTIAL ESTER OF A HYALURONIC ACID
WITH CHOLINE (30% of the carboxyls esterified)

6.21 g (10 mEq) of the tetrabutylammonium salt of
5 hyaluronic acid are solubilized in 160 ml of a mixture
of NMP/H₂O 95:5. The solution is cooled to 0°C and to
it is added 0.710 g (3.0 mEq) of
(2-bromoethyl)trimethylammonium bromide finely ground
and suspended in 10 ml of pure NMP. The suspension is
10 slowly added over 30 minutes while being constantly
stirred. 2 hours later the resulting mixture is heated
to 30°C and stirred for 14 hours.
To the reaction mixture are added 320 ml of ethyl
acetate. The precipitate thus formed is separated by
15 filtration, washed twice with 50 ml of ethyl acetate
and finally vacuum-dried. The solid matter is
solubilized in 150 ml of H₂O containing 1.5 g of NaCl
at 4°C. The solution is filtered and precipitated by
slowly adding 450 ml of 95% ethanol while stirring.
20 The precipitate, which constitutes the ester defined
in the heading, is separated by filtration, washed
twice with 50 ml of 95% ethanol and once with 50 ml of
acetone and finally vacuum-dried.
Yield = 4.03 g.

25 Quantitative determination of the choline,
performed according to the procedure of Kannosuke
Fujimori et al. (J. Chromatography 414, 167 [1987])
after the product has undergone alkaline hydrolysis in
NaOH 0.1N at 45°C for 30 minutes, shows a choline
30 content of 0.71 mEq/g.

Example 13:PREPARATION OF THE PARTIAL ESTER OF A HYALURONIC ACID
WITH CHOLINE (40% of the carboxyls esterified)

6.21 g (10 mEq) of the tetrabutylammonium salt of

- hyaluronic acid are solubilized in 160 ml of a mixture of NMP/H₂O 95:5. The solution is cooled to 0°C and to it is added 1.087 g (4.4 mEq) of (2-bromoethyl)trimethylammonium bromide finely ground and suspended in 10 ml of pure NMP. The suspension is slowly added over 30 minutes while being constantly stirred. 2 hours later the resulting mixture is heated to 30°C and stirred for 14 hours. To the reaction mixture are added 320 ml of ethyl acetate. The precipitate thus formed is separated by filtration, washed twice with 50 ml of ethyl acetate and finally vacuum-dried. The solid matter is solubilized in 150 ml of H₂O containing 1.5 g of NaCl at 4°C. The solution is filtered and then precipitated by adding 450 ml of 95% ethanol while stirring. The precipitate, which constitutes the ester defined in the heading, is separated by filtration, washed twice with 50 ml of 95% ethanol and once with 50 ml of acetone and finally vacuum-dried.
- Yield = 4.05 g.

- Quantitative determination of the choline, performed according to the procedure of Kannosuke Fujimori et al. (J. Chromatography 414, 167 [1987]) after the product has undergone alkaline hydrolysis in NaOH 0.1N at 45°C for 30 minutes, shows a choline content of 0.932 mEq/g.

Example 14:

Pharmaceutical preparations in packets containing granules to mix with water before use.

- Preparation No. 1: a packet containing granules, which contains:

active principle	400 mg
excipients:	
cross-linked sodium carboxymethylcellulose	450 mg

29

	colloidal silica	10 mg
	talc	30 mg
	aspartame	20 mg
	natural flavoring	q.b.
5	sucrose	q.s. to 3.500

Preparation No. 2: a packet containing granules,
which contains:

	active principle	800 mg
	excipients:	
10	cross-linked sodium carboxymethylcellulose	900 mg
	colloidal silica	20 mg
	talc	60 mg
	aspartame	40 mg
	natural flavoring	q.b.
15	sucrose	q.s. to 7.000

Preparation No. 3: a packet containing granules,
which contains:

	active principle	400 mg
	excipients:	
20	sodium carboxymethyl starch	400 mg
	colloidal silica	20 mg
	talc	30 mg
	aspartame	10 mg
	natural flavoring	q.b.
25	fructose	q.s. to 2.500

Preparation No. 4: a packet containing granules,
which contains:

	active principle	800 mg
	excipients:	
30	sodium carboxymethyl starch	800 mg
	colloidal silica	40 mg
	talc	60 mg
	aspartame	20 mg
	natural flavoring	q.b.

SUBSTITUTE SHEET

fructose

q.s. to 5.000

Preparation No. 5: a packet containing granules,
which contains:

	active principle	400	mg
5	excipients:		
	corn starch	700	mg
	talc	30	mg
	magnesium stearate	10	mg
	colloidal silica	10	mg
10	aspartame	20	mg
	natural flavoring		q.b.
	sucrose		q.s. to 3.500

Preparation No. 6: a packet containing granules,
which contains:

15	active principle	800	mg
	excipients:		
	corn starch	1.400	mg
	talc	60	mg
	magnesium stearate	20	mg
20	colloidal silica	20	mg
	aspartame	40	mg
	natural flavoring		q.b.
	sucrose		q.s. to 7.000

Preparation No. 7: a packet containing granules,
which contains:

25	active principle	400	mg
	excipients:		
	cross-linked polyvinylpyrrolidone	700	mg
	talc	30	mg
30	magnesium stearate	10	mg
	colloidal silica	10	mg
	aspartame	10	mg
	natural flavoring		q.b.
	fructose		q.s. to 2.500

Preparation No. 8: a packet containing granules,
which contains:

	active principle	800 mg
	excipients:	
5	cross-linked polyvinylpyrrolidone	1.400 mg
	talc	60 mg
	magnesium stearate	20 mg
	colloidal silica	20 mg
	aspartame	20 mg
10	natural flavoring	q.b.
	fructose	q.s. to 5.000

Preparation No. 9: a packet containing granules,
which contains:

	active principle	400 mg
15	excipients:	
	microcrystalline cellulose	500 mg
	sodium carboxymethylcellulose	200 mg
	mannitol	200 mg
	colloidal silica	10 mg
20	aspartame	10 mg
	natural flavoring	q.b.
	fructose	q.s. to 2.500

Preparation No. 10: a packet containing granules,
which contains:

25	active principle	800 mg
	excipients:	
	microcrystalline cellulose	1.000 mg
	sodium carboxymethylcellulose	400 mg
	mannitol	400 mg
30	colloidal silica	20 mg
	aspartame	20 mg
	natural flavoring	q.b.
	fructose	q.s. to 5.000

Example 15:

Pharmaceutical preparations in tablet form to be dissolved in the mouth.

Preparation No. 1: one tablet contains:

5	active principle	400 mg
	excipients:	
	sodium carboxymethyl starch	100 mg
	colloidal silica	10 mg
	talc	30 mg
10	magnesium stearate	10 mg
	natural flavoring	q.b.
	sucrose	q.s. to 1.300

Preparation No. 2: one tablet contains:

	active principle	400 mg
15	excipients:	
	corn starch	200 mg
	colloidal silica	10 mg
	talc	30 mg
	magnesium stearate	10 mg
20	natural flavoring	q.b.
	sucrose	q.s. to 1.300

Preparation No. 3: one tablet contains:

	active principle	400 mg
	excipients:	
25	microcrystalline cellulose	300 mg
	talc	20 mg
	magnesium stearate	10 mg
	natural flavoring	q.b.
	aspartame	q.b.
30	sucrose	q.s. to 1.300

Preparation No. 4: one tablet contains:

	active principle	400 mg
--	------------------	--------

SUBSTITUTE SHEET

excipients:

	lactose	250 mg
	talc	20 mg
	magnesium stearate	10 mg
5	aspartame	q.b.
	natural flavoring	q.b.
	sucrose	q.s. to 1.300

Preparation No. 5: one tablet contains:

	active principle	400 mg
10	excipients:	
	cross-linked polyvinylpyrrolidone	300 mg
	colloidal silica	20 mg
	talc	20 mg
	magnesium stearate	10 mg
15	natural flavoring	q.b.
	sucrose	q.s. to 1.300

Preparation No. 6: one tablet contains:

	active principle	400 mg
	excipients:	
20	sodium carboxymethyl starch	200 mg
	talc	30 mg
	magnesium stearate	10 mg
	corn starch	200 mg
	natural flavoring	q.b.
25	aspartame	q.b.
	microcrystalline cellulose	q.s. to 1.300

The following is claimed:

1.The use of choline esters of acidic polysaccharides selected from the group consisting of hyaluronic acid, alginic acid, gellan, oxidized cellulose, oxidized chitin, carboxy-hydrocarbylcellulose, carboxy-hydrocarbyl-starch and carboxy-hydrocarbyl-chitin, in which the hydrocarbyl is the residue of an alkyl, aralkyl or cycloalkyl group, or a metal or organic base salt thereof, as an anti-ulcer and gastroprotective agent.

2.The use of a choline ester according to claim 1, wherein the alkyl group is straight-chained and has a maximum of 6 carbon atoms.

3.The use of a choline ester according to claim 2. wherein the alkyl group is methyl.

4.The use of a choline ester according to claim 1, wherein the aralkyl group has a maximum of 6 carbon atoms in the alkyl part and wherein the aryl group is a benzene residue, unsubstituted or substituted by 1 to 3 lower alkyl or alkoxy groups having a maximum of 4 carbon atoms.

5.The use of a choline ester according to claim 4, wherein the alkyl groups are methyl groups.

6.The use of a choline ester according to claim 1, wherein the cycloalkyl group has a maximum of 6 carbon atoms in the ring optionally substituted by 1 to 3 methyl groups.

7.The use of a choline ester according to claim 1, wherein the polysaccharide is purified

hyaluronic acid extracted from cockscombs.

8. The use of a choline ester according to claim 1, wherein molecular fractions of hyaluronic acid with molecular weights varying between 90% and 0.2% of the molecular weight of the whole acid are used as starting acidic polysaccharides.

9. The use of a choline ester according to claim 8, wherein the polysaccharide is the commercially available product known as "non-inflammatory sodium hyaluronate-NIF-NaHA".

10. The use of a choline ester according to claim 8, wherein the polysaccharide is a hyaluronic acid fraction known as "Hyalastine" and having a mean molecular weight between 50,000 and 100,000.

11. The use of a choline ester according to claim 8, wherein the polysaccharide is a hyaluronic acid fraction known as "Hyalectin" having a mean molecular weight of between 500,000 and about 730,000.

12. The use of a choline ester according to claim 8, wherein the polysaccharide is a hyaluronic acid fraction having a mean molecular weight of between about 250,000 and about 350,000.

13. The use of a choline ester according to claim 1, wherein the polysaccharide is high-molecular-weight alginic acid.

14. The use of a choline ester according to claim 1, wherein the polysaccharide is low-molecular-weight alginic acid.

15. The use of a choline ester according to

SUBSTITUTE SHEET

claim 1, wherein the polysaccharide is gellan.

16. The use of a choline ester according to claim 1, wherein the polysaccharide is oxidized cellulose or basic carboxy-alkyl-cellulose derived from native cotton cellulose with about 3,000 units of glucose.

17. The use of a choline ester according to claim 1, wherein the polysaccharide is oxidized cellulose or basic alkyl-cellulose derived from mercerized or regenerated or degraded cellulose.

18. The use of a choline ester according to claim 1, wherein basic carboxyalkyl-starches derived from starches with varying contents of amylose and amylopectin are used as the starting polysaccharide.

19. The use of a choline ester according to claim 1, wherein basic carboxyalkyl-starches derived from starches constituted mainly by amylopectin are used as the starting polysaccharide.

20. The use of a choline ester according to claim 1, wherein basic carboxyalkyl-amides derived from dextrin are used as the starting polysaccharide.

21. The use of a choline ester according to any one of the previous claims, wherein total esters of the acidic polysaccharide are used as the starting polysaccharide.

22. The use of a choline ester according to any one of the previous claims, wherein partial esters of the acidic polysaccharide are used as the starting polysaccharide.

23. The use of a choline ester according to claim 22, wherein the ester is used in the form of one of its metal or organic base salts.

24. The use of a choline ester according to claim 23, wherein the salt is an alkali metal or alkaline earth salt.

25. The use of a choline ester according to claim 23, wherein the salt is the sodium, potassium or ammonium salt.

26. The use of a choline ester according to claim 23, wherein a salt of a therapeutically acceptable organic base is used.

27. The use of a choline ester according to claim 23, wherein a salt of a pharmacologically inactive base is used.

28. The use of a choline ester according to claim 23, wherein a salt of a pharmacologically active base which has an action that is compatible with the anti-ulcer and gastroprotective action of said choline ester is used.

29. The use of a choline ester according to claim 28, wherein a base which has itself an anti-ulcer and gastroprotective activity is used.

30. The use of a choline ester according to any one of claims 1-22, 26 and 27, wherein a choline salt is used as the starting polysaccharide.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 92/02133

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl.5 A 61 K 31/72

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System

Classification Symbols

Int.Cl.5

A 61 K

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP,A,0216453 (FIDIA S.p.A.) 1 April 1987, see pages 13,28-29,41-42 (cited in the application)	7-12
Y	---	1-6,13-30
Y	EP,A,0251905 (FIDIA S.p.A.) 7 January 1988, see page 6 (cited in the application)	1-30
Y	Clinical Pharmacy, vol. 10, no. 1, January 1991, B.A. McGEE et al.: "Current options for the treatment of systemic scleroderma", pages 14-25, see abstract	1-30
	-/-	

¹⁰ Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

21-12-1992

Date of Mailing of this International Search Report

10.02.93

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

Mme Dagmar FRANK

III. DOCUMENTS CONSIDERED TO BE RELEVANT

(CONTINUED FROM THE SECOND SHEET)

Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	US,A,2902479 (W.H. McNEELY et al.) 1 September 1959, see column 1 (cited in the application) ---	1-30
Y	BE,A, 897114 (F.I.R.M.A. S.p.A.) 17 October 1983, see pages 1-3 ---	1-30
Y	GB,A,1098980 (MEITO SANGYO K.K.) 10 January 1968, see pages 1-2; claims 1-5,7-10,15,16 ---	1-30
Y	EP,A,0092121 (THE UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS) 26 October 1983, see pages 1,7; claims 1,4 ---	1-30
Y	EP,A,0342557 (FIDIA S.p.A.) 23 November 1989, see abstract; columns 1,17 (cited in the application) -----	1-30

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9202133
SA 64481

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 27/01/93. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0216453	01-04-87	AU-B- 591501	07-12-89
		AU-A- 5983686	26-02-87
		JP-A- 62064802	23-03-87
		US-A- 4965353	23-10-90
		US-A- 4851521	25-07-89

EP-A- 0251905	07-01-88	AU-A- 7008491	16-05-91
		AU-B- 602901	01-11-90
		JP-A- 63033401	13-02-88
		US-A- 5147861	15-09-92
		ZA-A- 8704520	29-12-87

US-A- 2902479		None	

BE-A- 897114	17-10-83	None	

GB-A- 1098980		US-A- 3364111	

EP-A- 0092121	26-10-83	DE-A- 3374914	28-01-88
		JP-A- 59046221	15-03-84

EP-A- 0342557	23-11-89	AU-B- 629551	08-10-92
		AU-A- 3571889	29-11-89
		WO-A- 8910940	16-11-89
		JP-T- 2504164	29-11-90
		US-A- 5122598	16-06-92

EPO FORM P049

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82